These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6345112)

  • 21. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effects with oral 5-aminosalicyclic acid.
    Fardy JM; Lloyd DA; Reynolds RP
    J Clin Gastroenterol; 1988 Dec; 10(6):635-7. PubMed ID: 2906645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral balsalazide (Colazal) for ulcerative colitis.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
    Green JR; Swan CH; Rowlinson A; Gibson JA; Brown P; Kerr GD; Swarbrick ET; Thornton P
    Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo.
    Goerg KJ; Wanitschke R; Gabbert H; Breiling J; Franke M; Meyer zum Büschenfelde KH
    Digestion; 1987; 37(2):79-87. PubMed ID: 2887473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
    McIntyre PB; Rodrigues CA; Lennard-Jones JE; Barrison IG; Walker JG; Baron JH; Thornton PC
    Aliment Pharmacol Ther; 1988 Jun; 2(3):237-43. PubMed ID: 2908755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balsalazide disodium.
    Am J Health Syst Pharm; 2002 Jan; 59(1):27. PubMed ID: 11813462
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral mesalamine for ulcerative colitis.
    Med Lett Drugs Ther; 1992 Aug; 34(877):80-1. PubMed ID: 1353858
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
    Hanauer SB
    Gut; 1999 Apr; 44(4):455. PubMed ID: 10075949
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease.
    Bondesen S; Rasmussen SN; Rask-Madsen J; Nielsen OH; Lauritsen K; Binder V; Hansen SH; Hvidberg EF
    Acta Med Scand; 1987; 221(3):227-42. PubMed ID: 3296672
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
    Hanauer SB
    Am J Gastroenterol; 2003 Mar; 98(3):697-8. PubMed ID: 12650813
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disodium azodisalicylate. American College of Gastroenterology Committee on FDA-Related Matters.
    Levinson RA
    Am J Gastroenterol; 1985 Mar; 80(3):203-5. PubMed ID: 2858154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mesalamine wars heat up-enter balsalazide.
    Cohen RD
    Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.